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Abstract
Background: In X-linked dilated cardiomyopathy due to dystrophin mutations which abolish the expression of the
M isoform (5’-XLDC), the skeletal muscle is spared through the up-regulation of the Brain (B) isoform, a
compensatory mechanism that does not appear to occur in the heart of affected individuals.
Methods: We quantitatively studied the expression topography of both B and M isoforms in various human heart
regions through in-situ RNA hybridization, Reverse-Transcriptase and Real-Time PCR experiments. We also
investigated the methylation profile of the B promoter region in the heart and quantified the B isoform up
regulation in the skeletal muscle of two 5’-XLDC patients.
Results: Unlike the M isoform, consistently detectable in all the heart regions, the B isoform was selectively
expressed in atrial cardiomyocytes, but absent in ventricles and in conduction system structures. Although the level
of B isoform messenger in the skeletal muscle of 5’-XLDC patients was lower that of the M messenger present in
control muscle, it seems sufficient to avoid an overt muscle pathology. This result is consistent with the protein
level in XLDC patients muscles we previously quantified. Methylation studies revealed that the B promoter shows
an overall low level of methylation at the CG dinucleotides in both atria and ventricles, suggesting a methylation-
independent regulation of the B promoter activity.
Conclusions: The ventricular dilatation seen in 5’-XLDC patients appears to be functionally related to loss of the M
isoform, the only isoform transcribed in human ventricles; in contrast, the B isoform is well expressed in heart but
confined to the atria. Since the B isoform can functionally replace the M isoform in the skeletal muscle, its
expression in the heart could potentially exert the same rescue function. Methylation status does not seem to play
a role in the differential B promoter activity in atria and ventricles, which may be governed by other regulatory
mechanisms. If these mechanisms could be deduced, de-silencing of the B isoform may represent a therapeutic
strategy in 5’-XLDC patients.
Background
The dystrophin gene [GenBank at the NCBI:
NG_012232.1] encodes for a high molecular weight
cytoskeletal protein primarily expressed in the skeletal
and cardiac muscles, and to a lesser extent in smooth
muscles and brain. The large dystrophin gene generates
multiple transcripts, resulting in several isoforms, which
are produced by both alternative splicing events and tis-
sue-specific promoter usage. Seven promoters are
known to initiate dystrophin transcription; three of
these, the brain (B), muscle (M) and Purkinje (P) pro-
moters are clustered at the 5’ end of the gene and gen-
erate full length 14-Kb transcripts with an unique first
exon spliced to a shared set of 78 exons [1].
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The M transcript represents the prevalent dystrophin
isoform in both skeletal and cardiac muscles, whereas
the expression patterns of the other full-length dystro-
phin isoforms (B and P) have been less well character-
ized in these tissues. The B isoform has been
inconsistently detected in both the whole heart and ske-
letal muscle of adult human individuals [2-6]. In foetal
human tissues, the B transcript has been identified in
both the heart and in the skeletal muscle, although its
transcription appears to be activated at different devel-
opmental stages [6,7]. The dystrophin P isoform, on the
other hand, is undetectable in human foetal and adult
hearts and in foetal skeletal muscle [5-7], being confined
to adult skeletal muscle [5,6].
Dystrophin deficiency causes different allelic clinical
phenotypes, as Duchenne (DMD, OMIM 310200) and
Becker (BMD, OMIM 300376) muscular dystrophies;
the skeletal muscles are mainly affected but with the
progression of the disease there is also an overt cardio-
myopathy. In contrast, X-Linked Dilated Cardiomyopa-
thy (XLDC, OMIM 302045) due to dystrophin gene
mutations is characterized by selective cardiac disease
with no significant skeletal muscle symptoms [1]. None-
theless, elevated serum creatine kinase (CK) values in
this condition do suggest a subclinical skeletal muscle
involvement.
A classification of XLDC cases based on both molecu-
lar and clinical features has been proposed, distinguish-
ing milder forms with delayed presentation associated
with mutations in the spectrin-like dystrophin domain
(3’-XLDC) from the more severe early-onset forms
caused by 5’ dystrophin gene mutations (5’-XLDC) [8,9].
Notably, a significant group of 5’-XLDC mutations spe-
cifically affects the expression of the M isoform [10-15]
and result in a common transcriptional pattern charac-
terized by the up-regulation of dystrophin B (predomi-
nantly) and P isoforms in the skeletal muscle of patients
but not in the heart [7,10-12,15,16]. This transcriptional
behaviour has been suggested as the pathogenic basis
behind the exclusive cardiac involvement in 5’-XLDC; in
fact, while the cardiac tissue suffers from M isoform
deficiency, the skeletal muscle is spared as a result of
the compensatory up-regulation of B and P transcripts.
This view has been supported by the experimental
observation that the dystrophin muscle enhancer 1
(DME1), which is involved in the in vitro up-regulation
of B and P promoters, is active in skeletal but not in
cardiac muscle-derived cell lines [15]. The DME1 selec-
tive activation of P promoter in skeletal muscle has also
been confirmed in a transgenic mouse model in vivo
[17], thereby implicating the inability of DME1 to up-
regulate B and P isoform in the heart in the cardiac
pathology, at least in a murine model. Furthermore, the
DOT1L gene, which acts as a disruptor of telomeric
silencing, has recently been ascribed a regulatory role in
dystrophin expression in both the mdx mouse and
dilated cardiomyopathy (DCM) patient tissues [18]. This
observation directly implicates methylation regulation in
dystrophin expression, adding novel clues into the
pathogenesis of XLDC.
In order to shed more light on the mechanisms
behind the lack of compensatory up-regulation of the B
isoform in the 5’-XLDC heart, we investigated the tran-
scription pattern of the B isoform in normal human
heart compartments and in the whole human heart. We
also studied the methylation status of the B promoter in
heart compartments, looking in particular for regional
differences that could account for the variation observed
in isoform expression. Furthermore, we quantified the B
isoform up-regulation in the skeletal muscle of two 5’
XLDC patients lacking the M isoform [7,10] and com-
pared it to the normal level of dystrophin M transcript
in control skeletal muscle. We showed that, in contrast
to the M isoform, which is uniformly detectable in all
the heart regions, the B isoform is selectively expressed
in atrial cardiomyocytes, but absent in the ventricles and
in conduction system structures. Methylation studies of
the B promoter genomic region in the heart revealed a
uniformly homogeneous low level of methylation of CG
dinucleotides. No differences in the methylation status
were found between the atria and ventricles, thereby
suggesting that exists a methylation-independent regula-
tion of the B promoter activity. Thus, we speculate that
the B promoter activity might be driven by other regula-
tory mechanisms which need to be elucidated in order
to find strategies able to activate the B isoform tran-
scription; this could be of therapeutic value in 5’XLDC
patients.
Results
RT-PCR analysis
Reverse-Transcriptase (RT) PCR amplification of dystro-
phin B and M isoforms revealed different expression
patterns on RNA from both different human cardiac
areas and total human cardiac tissue; the M isoform was
found to be uniformly expressed in all the areas exam-
ined as was the housekeeping gene actin. In contrast,
the expected PCR product corresponding to the B iso-
form was detectable only in atrial samples; sequence
analysis confirmed this 514-bp PCR product as the
expected B-specific exon1-exon 6 dystrophin fragment
(data not shown).
RT-PCR product hybridization with an oligo probe spe-
cific for dystrophin exon 2 ruled out the occurrence of a
faint B isoform expression. Indeed this hybridization pat-
tern confirmed that the atrial structures represent the only
site of expression of the dystrophin B transcript in the
heart, showing a prevalence in the left atrium. Neither the
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ventricles nor total human cardiac tissue showed the pre-
sence of any hybridization signal (Figure 1a).
Real-time PCR analysis of B and M isoforms
Quantification of both B and M dystrophin transcripts
was performed on commercial human RNA (Ambion®,
Analytical Biological Services (ABS) Inc.) from total
heart, atria, ventricles and conduction system structures
(CCS); commercial RNA (Ambion®, Analytical Biologi-
cal Services (ABS) Inc.) from human skeletal muscle and
brain were used as controls. Expression of the M iso-
form was revealed in all samples examined, with the
highest score being found in the skeletal muscle (acting
as a calibrator), the lowest in the brain, and intermediate
values in total heart, atria and ventricles (Figure 1b).
The B isoform was detected at very low levels in the
control skeletal muscle and showed the highest level in
the brain (acting as a calibrator). Interestingly, B isoform
expression values were not uniform in cardiac areas; in
both ventricles and in total heart the B amplification
threshold cycle (CT) was undetermined in separate
experiments with different amounts of cDNA, thereby
confirming the findings observed in RT-PCR experi-
ments. In the atria, particularly the left, the level of
expression was higher than in skeletal muscle. We pos-
tulate that the failure to detect the B messenger in the
human cardiac tissue as a whole could be due to the
prevalent ventricular origin of the commercial RNA
used (Ambion®, Analytical Biological Services (ABS)
Inc) (Figure 1c).
In the CCS compartments (sinoatrial and atrioventri-
cular nodes, bundle of His and Purkinje fibres) the M
isoform was expressed at similar levels to actin com-
pared to the skeletal muscle as an internal calibrator
(Figure 1b). In repeated experiments with increasing
amounts of cDNA on the same samples, the B amplifi-
cation CT was undetermined (Figure 1b), thereby impli-
cating atrial cardiomyocytes as the elective site of
expression of the cardiac B messenger.
In the skeletal muscle of two unrelated 5’ XLDC
patients (LT and SA, previously described [10,14]) the
M amplification CT was undetermined, as expected due
to their particular genomic mutation (data not shown).
The B isoform expression values confirmed the up-
Figure 1 a. Hybridization of dystrophin B isoform RT-PCR (oligonucleotides within B exons 1 and 6; expected product: 514 bp) with an
internal oligo probe (within exon 2) that confirmed its expression in both Atria (lanes 2 and 4) and in the control brain (lane 6), and
its absence in the Ventricles and Total Heart. b Levels of dystrophin M transcript expression (2-ΔΔCT values) using the skeletal muscle as
internal calibrator and actin as reference gene in: Skeletal Muscle, Total heart, Right Atrium, Right Ventricle, Left Atrium, Left Ventricle, Sinoatrial
(SA) Node, Atrioventricular (AV) Node, Bundle of His and Purkinje Fibres. The M isoform was expressed in all the samples studied, featuring the
lowest score in Brain. c Levels of dystrophin B transcript expression (2-ΔΔCT values) using the brain as internal calibrator and actin as reference
gene in the same samples. In both the ventricles the B amplification threshold cycle (CT) was undetermined, as well as in the total heart and in
the conduction system structures. In the atria the score obtained was higher than that in skeletal muscle, in particular in the left atrium.
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regulation previously detected in RT-PCR experiments
[10,14]. Application of the equation 2-ΔΔCT to the
expression of B isoform in patient skeletal muscle, as
compared to a control skeletal muscle, yielded results of
25 and 9 in patients LT and SA, respectively, using actin
as the reference gene (Figure 2a).
We compared the level of the B dystrophin transcript
in the skeletal muscle of these patients with the level of
total dystrophin transcript in a normal muscle (almost
exclusively driven by the M promoter). In both patients
the dystrophin messenger was found to be quantitatively
reduced with respect to healthy control muscle (2-ΔΔCT
0.67 and 0.28 in LT and SA, respectively) (Figure 2b).
Nevertheless, the amount of the B dystrophin transcript
is still sufficient to guarantee protein levels (57% in LT
and 29% in SA) able to avert muscular dystrophy, as we
have previously reported [10].
In-situ hybridization
Non-radioactive in-situ hybridization experiments were
carried out with isoform-specific riboprobes on a human
left ventricle sample; whereas the M probe displayed an
intense hybridization signal, the B probe failed to hybri-
dize, thereby confirming the lack of B expression in this
heart compartment (Figure 3). These data confirm that
the B isoform has a topographically specific expression
in the different heart compartments and further support
the results of Reverse-Transcriptase and Real-Time PCR
experiments.
Methylation analysis
Analysis of the B promoter genomic region in the heart
showed an overall low level of methylation of CG dinu-
cleotides, a finding which could indicate the presence of
a CpG island in that region. On the other hand, com-
parison of the methylation status of DNA extracted
from atria and ventricles revealed no significant differ-
ences; this could be a clue that the regulation of B iso-
form expression in the heart compartments is driven by
a mechanism other than promoter methylation (Figure
4).
Discussion
In medical genetics, XLDC represents an interesting
example of a Mendelian disease due to mutations that
selectively affect different tissues/compartments. Clearly,
the elucidation of the pathogenic model(s) of this rare
phenotype may impact on the correction strategies aim-
ing at rescuing dystrophin function in the heart.
Although the explanation of the isolated cardiac involve-
ment in XLDC remains controversial, many reports have
indirectly suggested that it may be due to the inability of
the heart to up-regulate the B-isoform to compensate
for the lack of M isoform transcription, which is selec-
tively abolished by specific mutations in the 5’ region of
the gene.
In order to unequivocally define the topography of B
isoform distribution and its regulatory aspects in the
heart, we investigated the expression of dystrophin
Figure 2 a. Levels of dystrophin B transcript expression (2-ΔΔCT values) in the skeletal muscle of two 5’XLDC patients (LT and SA), as
compared to a control muscle (calibrator), using actin as reference gene. B upregulation resulted in 25- and 9-fold transcript levels in LT
and SA, respectively. b Levels of dystrophin B transcript (2-ΔΔCT values) in the skeletal muscle of the same 5’XLDC patients, as compared to the
level of dystrophin M transcript in a skeletal muscle control using actin as reference gene. The ratio was 0.67 and 0.28 in patients LT and SA,
respectively.
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isoforms M and B in different compartments of the nor-
mal human cardiac muscle. This revealed that while the
M isoform is uniformly expressed in the whole heart,
including cardiac atria, ventricles and conduction system
structures (CCS), the transcription of the B isoform is
confined to the atria and absent in both ventricles and
CCS. We support this finding by Reverse-Transcriptase
and Real-time PCR assays, as well as in-situ RNA
hybridisation.
This is the first clear demonstration that the B tran-
script is absent in normal human heart ventricles, struc-
tures dedicated to contractile function and primarily
affected in XLDC. Furthermore, these data support the
hypothesis that the abolition by 5’ dystrophin mutations
of M transcript, which we demonstrate is the exclusive
dystrophin isoform present in the heart ventricles, is the
pathogenic mechanism leading to the selective cardiac
involvement in patients with 5’ -XLDC. In fact the ske-
letal muscle in these 5’-XLDC patients seems to be able
to compensate for the absence of the M isoform by up-
regulating B-isoform expression. The inability of the
heart to benefit from the up-regulation of the B isoform
is related to its peculiar expression topography. In keep-
ing with our molecular findings, echocardiographic clues
for the diagnosis of XLDC consist of the detection of
ventricular non-compaction and localized inferobasal
Figure 3 Non-radioactive in-situ RNA hybridization on cryosections obtained from the left ventricle of an explanted human heart.
Isoform-specific RNA probes recognized the 5’ UTR region and first exon of B and M isoforms. The M antisense probe (M9 top right) displayed
an intense signal of hybridization whereas the B antisense probe failed to hybridize (B4 top left). Both the M (M10 bottom right) and B sense
(B5 bottom left) probes failed to hybridize.
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Figure 4 Methylation status of the B promoter CpG islands in heart ventricle and atrium. A) Schematic representation of the B isoform
(Dp427c) promoter. Grey arrow indicates the transcription start site of the Dp427c mRNA. The DNA sequence and distribution of the CG
dinucleotides is shown B) Prediction of the putative CpG island in the B promoter using the Emboss CpGplot algorithm C) Percentage of
methylated cytosines within the putative CpG island in DNA extracted from ventricle and atrium muscle tissue, respectively.
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left ventricular hypokinesia/akinesia, with no sign of pri-
mary atrial involvement [19]. It therefore appears that
the pathogenesis of 5’ XLDC is due to the loss of the
only isoform physiologically transcribed in these struc-
tures, the M isoform.
Moreover, our data attest to the existence of regional
intra-cardiac differences in representation of dystrophin
B-isoform mRNA, to our knowledge for the first time.
Atrial and ventricular myocardia exhibit fundamental
differences, not only in their morphology, but also in
their ultrastructure and function; indeed, the ventricular
myocardium functions primarily as a contractile pump,
whereas atrial myocardium has prominent neuroendo-
crine and chronotropic regulatory functions. It has been
suggested that these differences could be related to the
existence of a chamber-specific transcriptome, with ven-
tricular myocytes expressing genes to meet contractile
and energetic demands and atrial myocytes possessing
transcriptional activity related to signal transduction and
cell-cell communication [20]. From this perspective, the
selective atrial expression of the B-dystrophin isoform
could be related to the role of this isoform in signalling
pathways, in keeping with its primary expression in the
central nervous system. In the mature brain, the B iso-
form is preferentially expressed in specific regional neu-
ronal subpopulations and localizes to punctate
structures, which seem to correspond to a subset of
GABAergic synapses [21]; experimental evidence has
suggested a role for this isoform in maintaining cellular
calcium homeostasis and calcium-related intra- and
inter-cellular signalling [22,23].
Atrium-specific gene expression invariably appears to
be achieved through the silencing of gene expression in
the ventricular compartment during development [24].
This has been demonstrated experimentally for genes
MLC2a (Myosin Light Chain atrial), slow MyHC3 (Slow
Myosin Heavy Chain) and ANF (Atrial Natriuretic Fac-
tor) [25-27]. We speculate that the differences in B-iso-
form expression between atria and ventricles in the
adult heart could be the result of a similar silencing
mechanism, which occurs during development and pri-
vileges the exclusive expression of the M isoform, due
to its primary contractile function in ventricles. Consid-
ering the very high rate of ATP consumption, linked to
the sarcomeric activity, in the ventricles, it is not sur-
prising that cardiomyocytes favour the transcription
(known to be a high-cost process for the cell) of only
one full-length dystrophin messenger [8]. However, this
selective transcription pattern seems to expose the ven-
tricles to mutations affecting M isoform synthesis,
including XLDC and dystrophinopathies in general.
The B promoter belongs to a family of ancient, pro-
karyotic-like CAAT- and TATA-less promoters, which
are known to display low responsiveness to regulation
through CpG island methylation by methyl-binding pro-
teins [2,28]. Indeed, we described a low methylation
level of CG dinucleotides of the B promoter and no dif-
ferences of methylation between atria and ventricles,
supporting that the regulation of the B isoform expres-
sion in the heart compartments is driven by a mechan-
ism other than promoter methylation. These data,
associated to the evidence that DME1 enhancer (acting
in a pre-transcriptional mechanism) and DOT1 (a telo-
meric silencing inhibitor, which acts at post-transcrip-
tional level) both regulate the dystrophin isoforms in the
heart [18], reveal further complexity in the tissue-/com-
partment-specific control of dystrophin gene expression.
It is likely that genomic regions surrounding the B and
M promoters, as well as genomic regions upstream of
the gene, could harbour elements that orchestrate the
expression of full-length isoforms in a particular tissue
in a time-specific way. In particular, locus control
regions (LCR) are the DNA sequences that define a
chromatin domain of an independent regulatory envir-
onment, and are characterized by a set of DNase-I
hypersensitive sites (HSS), which contain binding sites
for a variety of regulatory proteins. Several studies have
suggested that LCRs are indispensable for appropriate
execution of a developmental regulation programme
[29-31]. In addition, post-transcriptional regulatory
mechanisms such as those highlighted by RNA silencing
(RNAsi), orchestrated by a variety of small RNAs, could
play a relevant role in dystrophin expression modulation,
as recently reported [32,33].
Although a major non-mechanical function of the B
isoform seems to be supported by its atrial and central
nervous system expression, the up-regulation of this iso-
form in the skeletal muscle of 5’-XLDC patients is
clearly capable of protecting muscle from progressive
muscle degeneration. This suggests that this isoform has
preserved structural potential, which is not surprising,
as the difference between the M and B isoforms is con-
fined to the amino-acids encoded by exon 1 (eleven for
the M isoform and three for the B isoform), leaving the
actin and beta dystroglycan domains of dystrophin
intact.
Conclusions
Investigation of the distribution pattern of full-length
dystrophins in cardiac muscle revealed a difference in
the expression of M and B isoforms between atria and
ventricles. Nonetheless, despite the identification of the
various core promoters and enhancer regions, the
mechanisms underlining differences in regulation of dys-
trophin transcription between cardiac and skeletal mus-
cle are still not entirely clear. From our data it is
evident that dystrophin transcription by the various pro-
moters is characterized by tissue selectivity rather than
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tissue specificity; these promoters are active, albeit at
different levels, in different tissues and are developmen-
tally regulated. Moreover, for the first time we demon-
strate the existence of regional intra-cardiac differences
in the representation of dystrophin B isoform mRNA,
allowing us to shed more light on the pathogenesis of 5’
XLDC.
The selective atrial expression of B isoform and the
evidence that the B isoform is able to functionally
replace the M isoform in the skeletal muscle may open
novel therapeutic windows for patients suffering from 5’
XLDC and dystrophinopathies in general.
In this view it appears promising a drug discovery
approach which aims at searching for molecules/drugs
able to specifically activate B promoter in human heart
ventricles and thereby restoring dystrophin synthesis.
Methods
Reverse-transcription PCR (RT-PCR)
B and M dystrophin transcripts were analysed by PCR
amplification of reverse-transcribed commercial RNA
(Ambion® Analytical Biological Services (ABS) Inc.) of
human total heart as well as of different cardiac areas,
i.e. right and left atria and ventricles. Reverse tran-
scription (RT) was performed using a high capacity
cDNA reverse-transcription kit (Applied Biosystems),
according to the protocol supplied. The B and M tran-
scripts were amplified by means of an exon-specific
forward oligonucleotide and a reverse primer located
in exon 6 (sequences are available upon request). As
housekeeping gene, we amplified the actin gene on the
same samples (primer sequences are available upon
request).
PCR was carried out in a reaction volume of 25 μl
containing the cDNA template, 2.5 U Ex Taq polymer-
ase (Takara), 1× Ex Taq Buffer, 1.5 mM MgCl2, 200 μM
dNTPs, and 0.5-1 μM of each primer. Amplification
conditions were as follows: initial denaturation (2 min)
at 94°C, denaturation (30 s) at 94°C, annealing (30 s) at
63°C, extension for 5 cycles at 68°C (30 s), followed by
denaturation at 94°C (30 s), annealing at 62°C (30 s),
extension (45 s) for 30 cycles at 68°C, and final exten-
sion at 68°C (3 min). 10 μl of the PCR reaction mixture
was analysed on 1.3% agarose gel. RT-PCR products of
B amplification were purified from the gels, cloned into
pCR II vector (Invitrogen) and sequenced with M13 and
T7 primers, using a Big Dye terminator cycle sequen-
cing kit, and analysed using ABI Prism 3130 (PE
Applied Biosystems).
One aliquot of the PCR reaction mixture was trans-
ferred onto a GeneScreen Plus (NEN) membrane in SSC
10× buffer. RT-PCR products were hybridized with an
internal oligo probe (exon2F: 5’ TGGGTAA ATGCACA
ATTT TCTAAG 3’), according to standard procedures.
RNA isolation from 5’ XLDC patient skeletal muscle
biopsy samples
The genotype characterization of the two 5’-XLDC
patients studied, as well as their transcription patterns
of dystrophin isoforms in the skeletal muscle, has been
previously reported. The first patient (LT) possesses a
splice site mutation in the first intron of the M isoform
pre-mRNA [10], while the second patient (SA) features
a deletion removing the muscle promoter and first mus-
cle exon [14].
Total RNA was isolated from frozen skeletal muscle
biopsies from the patients using an RNeasy Kit (Qiagen),
following the manufacturer’s instructions. Before cDNA
synthesis, RNA was treated with DNAse I (Roche) and
checked for residual DNA contamination using 55-cycle
PCR.
Real-time PCR analysis of B and M isoforms in control
heart areas and 5’ XLDC patient skeletal muscle
Real-time PCR was carried out using the GeneAmp
Sequence Detection System 7300 (Applied Biosystems).
Commercial RNAs (Ambion®, Analytical Biological Ser-
vices (ABS) Inc.) from the following human samples
were studied: skeletal muscle, brain, total heart, right
atrium, right ventricle, left atrium, left ventricle, sinoa-
trial node, atrioventricular node, bundle of His and Pur-
kinje fibres. Furthermore, RNA extracted from the
skeletal muscle of two 5’-XLDC patients was analysed as
previously described.
Primer Express® Software was used for the selection
of primers and MGB probes (FAM-labelled) on the
5’UTR and first exon of B and M dystrophin isoforms.
Real-Time assay sequences are available upon request.
Real-Time PCR was performed in triplicate in a 96-well
plate; each 25 μl reaction consisted of 1× Taqman Master
Mix (Applied Biosystems), 300 nM forward and reverse
primers, 100 nM Taqman probes and 20 ng cDNA. For
the reference gene actin (ACTB), a TaqMan Endogenous
control assay was utilized (ID 4333762F Applied Biosys-
tems) according to the protocol supplied. The PCR con-
ditions for all analysed genes were as follows: pre-heating
at 50°C for 2 min and 95°C for 10 min; and cycling, 40
cycles at 95°C for 15 s and 60°C for 1 min.
The data obtained were analysed by the comparative
CT method (DDCt Method) (Applied Biosystems User
Bullettin #2), which evaluates the expression of the tar-
get genes (M and B dystrophin) with respect to that of
the reference gene (actin), and normalizes these values
relative to a calibrator sample (control Skeletal Muscle
or control Brain).
In-situ hybridization (ISH)
Non-radioactive in-situ hybridization was performed on
cryosections (18 micron thickness) obtained from the
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left ventricle of an explanted human heart. Two series of
seriate sections were prepared on each slide, and in each
ISH experiment four slides from independent series
were used. Probes were obtained by genomic amplifica-
tion of the full 5’UTR regions and first exons of dystro-
phin M and B isoforms (oligonucleotide sequences are
available upon request). For M isoforms the amplifica-
tion product was 333 bp and for B isoforms the amplifi-
cation product was 469 bp. PCR products were cloned
into pCRII vector (Invitrogen). RNA probes (antisense
and sense as negative controls) were obtained by in-
vitro transcription with T7 RNA polymerase of about 1
ug of linearized plasmid, using a DIG RNA labelling kit
from Roche according to the protocol supplied. ISH
experiments were performed as previously described
[34].
Methylation analysis
2 μg of genomic DNA extracted from the atrium and
ventricle were treated with sodium bisulphite using the
methylation gold kit (Zymoresearch). After purification,
the DNA was amplified by PCR and cloned within the
PGEM-T-easy vector (Promega). The sequences of the
oligonucleotides used for amplification are the following:
promB forward, AGAGATTTGTAGATTTATTGTT-
TTT; promB reverse, CAATCATTTATTATACAAC-
TACTACAAC. Twenty independent recombinant
clones (ten from atrial DNA and ten from ventricle
DNA) were selected, purified and sequenced. The DNA
sequence of each recombinant clone was compared to
the sequence of the B promoter genomic region
reported in the database [GenBank at the NCBI:
NG_012232.1]. Conversion of Cs to Ts indicated that Cs
were unmethylated in the original DNA, whereas con-
servation of the Cs indicated that the Cs were
methylated.
The studies have been carried following the ethical
approval of the local ethical committee (UNIFE) n. 9/
2005. Written informed consent for participation in the
study was obtained from participants.
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